… on several different issues around Advanced Therapy Medicinal Products (ATMPs). …
Advanced therapy medicinal products and health technology assessment principles and practices …

… Clinical studies need to be designed to align with health technology assessment requirements,
including generic quality of life, and payers should aim for clarity of criteria. Regulators …

… of medicine, pricing and reimbursement issues, technology adoption and permeation of
innovative advanced therapy medicinal products … & Regenerative Medicine International Society …

… Pricing and Reimbursement of Medicinal Products In Slovakia, a single application is
filed for both the pricing and the reimbursement of medicinal products. However, in the following …

… , health technology assessment, market authorization, and reimbursement program, as
well as a patient outreach program to improve patient access. A next level of innovation and …

… therapies and cellular therapies, with the regulatory terminology for advanced therapy
medicinal products … , as for human cells and tissue products [9]. The FDA’s Office of Tissues and …

… Assessing these medicines has therefore posed challenges for both regulators and Health
Technology Assessment (HTA) decision makers. Despite having been mentioned in the …

… Advanced therapy medicinal products (ATMPs) are a group of … products for human use that
comprises somatic cell therapy … Advanced therapy medicinal products (ATMPs) are a large …

… face when using advanced therapy medicinal products at the different … Advanced therapy
medicinal products: value judgement and ethica evaluation in health technology assessment …

… expertise and their involvement in health technology assessments are even more crucial
for … Assessments of ATMPs should follow the same principles as those of the medication …